Dawnrays Pharmaceutical (Holdings) Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Dawnrays Pharmaceutical (Holdings).

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	11.6%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Earnings Might Not Be As Promising As They Seem

Sep 21

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.065

Apr 08

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Is Due To Pay A Dividend Of CN¥0.065

Mar 25

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.015

Aug 30

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Shareholders Will Receive A Bigger Dividend Than Last Year

May 26

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.073

Apr 04

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Sep 19

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Solid Profits Have Weak Fundamentals

Sep 22

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of HK$0.015

Sep 12

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be HK$0.015

Aug 29

Here's How We Evaluate Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Dividend

Feb 28

Would Shareholders Who Purchased Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Stock Five Years Be Happy With The Share price Today?

Feb 07

Yung Lai Hung Is The Co-Founder & Executive Director of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) And They Just Picked Up 34% More Shares

Jan 14

Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Dec 22

What Kind Of Investors Own Most Of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)?

Dec 09

Three Things You Should Check Before Buying Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) For Its Dividend

Nov 23

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Dawnrays Pharmaceutical (Holdings) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:2348 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	1,079	563	125	317	N/A
3/31/2024	1,115	445	126	328	N/A
12/31/2023	1,151	326	126	338	N/A
9/30/2023	1,228	384	123	348	N/A
6/30/2023	1,304	442	119	357	N/A
3/31/2023	1,291	400	164	396	N/A
12/31/2022	1,278	358	209	434	N/A
9/30/2022	1,229	361	156	472	N/A
6/30/2022	1,180	363	104	509	N/A
3/31/2022	1,173	361	47	451	N/A
12/31/2021	1,165	358	-10	393	N/A
9/30/2021	1,155	332	-3	355	N/A
6/30/2021	1,144	305	4	318	N/A
3/31/2021	1,084	287	51	310	N/A
12/31/2020	1,024	268	99	303	N/A
9/30/2020	986	251	134	304	N/A
6/30/2020	948	235	170	305	N/A
3/31/2020	949	245	186	290	N/A
12/31/2019	950	255	201	276	N/A
9/30/2019	946	272	212	271	N/A
6/30/2019	943	288	223	266	N/A
3/31/2019	946	296	224	270	N/A
12/31/2018	949	304	226	274	N/A
9/30/2018	947	307	N/A	N/A	N/A
6/30/2018	946	310	311	336	N/A
3/31/2018	914	302	N/A	364	N/A
12/31/2017	882	293	N/A	391	N/A
9/30/2017	861	288	N/A	N/A	N/A
6/30/2017	839	283	N/A	310	N/A
3/31/2017	832	275	N/A	315	N/A
12/31/2016	824	266	N/A	320	N/A
9/30/2016	870	273	N/A	314	N/A
6/30/2016	915	279	N/A	308	N/A
3/31/2016	950	291	N/A	303	N/A
12/31/2015	985	302	N/A	298	N/A
9/30/2015	924	280	N/A	322	N/A
6/30/2015	863	258	N/A	346	N/A
3/31/2015	823	231	N/A	362	N/A
12/31/2014	784	205	N/A	378	N/A
9/30/2014	831	191	N/A	356	N/A
6/30/2014	878	177	N/A	333	N/A
3/31/2014	896	165	N/A	282	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 2348's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 2348's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 2348's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 2348's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 2348's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 2348's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/20 20:38
End of Day Share Price	2025/01/20 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Dawnrays Pharmaceutical (Holdings) Limited is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Wing-Tai Ng	China Galaxy International Securities (Hong Kong)
Wai Chak Yuen	Cinda International Research Limited
Iris Wang	Credit Suisse

Dawnrays Pharmaceutical (Holdings) Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Investor sentiment improves as stock rises 16%

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Earnings Might Not Be As Promising As They Seem

New major risk - Earnings quality

Dawnrays Pharmaceutical (Holdings) Limited Appoints Yu Liwei as Chief Executive Officer

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Dawnrays Pharmaceutical (Holdings) Limited Announces Resignation of Wu Weixian as Chief Executive Officer

Upcoming dividend of HK$0.015 per share

First half dividend of HK$0.015 announced

First half 2024 earnings released: EPS: CN¥0.33 (vs CN¥0.17 in 1H 2023)

Dawnrays Pharmaceutical (Holdings) Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 03 October 2024, Payable on 03 October 2024

Dawnrays Pharmaceutical (Holdings) Limited to Report First Half, 2024 Results on Aug 23, 2024

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.065

Dawnrays Pharmaceutical (Holdings) Limited Approves to Declare A Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.065 per share

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.065

Full year 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.24 in FY 2022)

Dawnrays Pharmaceutical (Holdings) Limited, Annual General Meeting, May 24, 2024

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.065

Dawnrays Pharmaceutical (Holdings) Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 June 2024

Dawnrays Pharmaceutical (Holdings) Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 June 2024

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Is Due To Pay A Dividend Of CN¥0.065

Final dividend of HK$0.065 announced

Full year 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.24 in FY 2022)

Dawnrays Pharmaceutical (Holdings) Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

Upcoming dividend of HK$0.015 per share at 7.1% yield

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.015

First half 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.12 in 1H 2022)

Dawnrays Pharmaceutical (Holdings) Limited to Report First Half, 2024 Results on Aug 25, 2023

Dawnrays Pharmaceutical (Holdings) Limited Announces the National Medical Products Administration Accepts the New Drug Application for Ebronucimab Injection

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Shareholders Will Receive A Bigger Dividend Than Last Year

Dawnrays Pharmaceutical (Holdings) Limited Approves Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.073 per share at 6.2% yield

Chief Executive Officer recently bought HK$2.6m worth of stock

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.073

Full year 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.24 in FY 2021)

Insufficient new directors

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Dawnrays Pharmaceutical (Holdings) Limited(SEHK:2348) dropped from S&P Global BMI Index

Upcoming dividend of HK$0.015 per share

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.11 in 1H 2021)

Dawnrays Pharmaceutical (Holdings) Limited Announces Interim Semi-Annual Ordinary Dividend for the Six Months Ended 30 June 2022, Payable on 05 October 2022

Dawnrays Pharmaceutical (Holdings) Limited to Report First Half, 2022 Results on Aug 26, 2022

Dawnrays Pharmaceutical (Holdings) Limited Declares Final Dividend for the Year Ended December 31, 2021

Upcoming dividend of HK$0.065 per share

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Insufficient new directors

Dawnrays Pharmaceutical (Holdings) Limited, Annual General Meeting, May 27, 2022

Dawnrays Pharmaceutical (Holdings) Ltd Ordinary Shares Deleted from Other OTC

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Dawnrays Pharmaceutical (Holdings) Limited Announces Final Dividend for the Year Ended 31 December 2021, Payable on 15 June 2022

Dawnrays Pharmaceutical (Holdings) Limited Announces Resignation of Chen Shaojun as Executive Director, Effective February 16, 2022

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Solid Profits Have Weak Fundamentals

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of HK$0.015

Dawnrays Pharmaceutical (Holdings) Limited Announces Initiation of Phase III Clinical Trial for Primary Hypercholesterolemia

First half 2021 earnings released: EPS CN¥0.11 (vs CN¥0.084 in 1H 2020)

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be HK$0.015

CEO & Executive Director recently bought HK$349k worth of stock

Dawnrays Pharmaceutical (Holdings) Limited Approves Special Dividend for the Year Ended 31 December 2020

Upcoming dividend of HK$0.10 per share

Investor sentiment improved over the past week

Co-Founder & Executive Director recently bought HK$573k worth of stock

Full year 2020 earnings released: EPS CN¥0.17 (vs CN¥0.16 in FY 2019)

Dawnrays Pharmaceutical (Holdings) Limited Recommends Special Dividend for the Year Ended 31 December 2020

Co-Founder & Executive Chairman recently bought HK$425k worth of stock

Co-Founder & Executive Chairman recently bought HK$231k worth of stock

Full year 2020 earnings released

Dawnrays Pharmaceutical (Holdings) Limited to Report Fiscal Year 2020 Results on Mar 26, 2021

Here's How We Evaluate Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Dividend

Would Shareholders Who Purchased Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Stock Five Years Be Happy With The Share price Today?

Yung Lai Hung Is The Co-Founder & Executive Director of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) And They Just Picked Up 34% More Shares

Co-Founder & Executive Director recently bought HK$263k worth of stock

Investor sentiment deteriorated over the past week

Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

What Kind Of Investors Own Most Of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)?

New 90-day high: HK$1.04